Perkins Capital Management’s Journey Medical DERM Stock Holding History

Perkins Capital Management’s Portfolio DERM Stock Details DERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-22,000	Closed	-$124K	–	82
2024 Q3	$124K	Hold	22,000	–	–	0.12%	76
2024 Q2	$124K	Hold	22,000	–	–	0.12%	79
2024 Q1	$81K	Sell	22,000 -10,000	-31%	-$43.5K	0.07%	85
2023 Q4	$184K	Sell	32,000 -192,295	-86%	-$856K	0.16%	84
2023 Q3	$615K	Sell	224,295 -2,100	-0.9%	-$4.69K	0.61%	47
2023 Q2	$360K	Buy	226,395 +8,000	+4%	+$12.9K	0.31%	70
2023 Q1	$343K	Sell	218,395 -7,405	-3%	-$13.8K	0.32%	68
2022 Q4	$434K	Buy	225,800 +16,850	+8%	+$33.3K	0.46%	60
2022 Q3	$514K	Sell	208,950 -11,100	-5%	-$37.8K	0.58%	53
2022 Q2	$823K	Buy	220,050 +28,300	+15%	+$112K	0.85%	44
2022 Q1	$926K	Buy	191,750 +50,950	+36%	+$254K	0.76%	51
2021 Q4	$758K	Buy	+140,800	New	+$1.02M	0.51%	61

Other funds holding DERM

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

Perkins Capital Management's DERM Position: Q4 2024 in Review

Perkins Capital Management sold out of Journey Medical (DERM) in Q4 2024, closing a stake of 22,000 shares — an estimated $124K sold.

Perkins Capital Management first reported a position in DERM in Q4 2021 and held it in 12 quarters. The position peaked at $926K in Q1 2022. 37 funds tracked by Wall St. Rank hold DERM as of Q4 2024.

Perkins Capital Management reported no remaining Journey Medical position as of Q4 2024 after selling out during the quarter.
Perkins Capital Management sold 22,000 Journey Medical shares in Q4 2024, an estimated $124K.
Perkins Capital Management first reported a position in Journey Medical in Q4 2021 and held it in 12 quarters.
Perkins Capital Management's Journey Medical position peaked at $926K in Q1 2022.
37 funds tracked by Wall St. Rank held Journey Medical as of Q4 2024.

Based on Perkins Capital Management's 13F filing for Q4 2024, filed 11 Feb 2025.